Comprehensive Guide to Zafirlukast: Uses, Dosage, Side Effects, and More
What is Zafirlukast?
Overview of Zafirlukast
Generic Name: Zafirlukast
Brand Name: Accolate, generics
Drug Group: Leukotriene receptor antagonist (anti-asthmatic)
Commonly Used For
- Prevent asthma attacks.
- Manage allergic rhinitis symptoms.
- Reduce inflammation in chronic asthma.
Key Characteristics
Form: Oral tablets (10 mg, 20 mg) (detailed in Dosage section).
Mechanism: Selectively inhibits cysteinyl leukotriene receptor 1 (CysLT1), reducing bronchoconstriction and inflammation.
Approval: FDA-approved (1996 for Accolate) and EMA-approved for asthma prophylaxis.
Indications and Uses of Zafirlukast
Zafirlukast is indicated for respiratory conditions, leveraging its anti-inflammatory properties to control asthma and related disorders:
Chronic Asthma: Prevents asthma symptoms in adults and children (5+ years), reducing daytime and nighttime attacks, supported by long-term clinical studies over 12 weeks.
Allergic Rhinitis: Manages seasonal and perennial allergic rhinitis, alleviating nasal congestion and sneezing, used off-label with evidence from allergy research.
Exercise-Induced Bronchoconstriction (EIB): Reduces EIB in asthmatic patients, improving exercise tolerance, with data from pulmonary function studies.
Aspirin-Exacerbated Respiratory Disease (AERD): Treats AERD in patients with asthma and aspirin sensitivity, decreasing polyp formation and symptom severity, supported by otolaryngology trials.
Chronic Obstructive Pulmonary Disease (COPD): Investigated off-label to manage COPD with asthmatic features, improving airflow, with emerging pulmonology evidence.
Atopic Dermatitis: Explored off-label to reduce inflammation in severe atopic dermatitis, with dermatologic studies showing modest benefits.
Eosinophilic Esophagitis (EoE): Used off-label to control eosinophilic inflammation in EoE, improving swallowing and reducing esophageal damage, supported by gastroenterology research.
Urticaria: Managed off-label for chronic idiopathic urticaria, reducing hive frequency, with data from allergy and immunology cohorts.
Bronchopulmonary Dysplasia (BPD): Investigated off-label in preterm infants with BPD, improving respiratory outcomes, with cautious use under neonatal pulmonology supervision.
Post-Viral Respiratory Inflammation: Explored off-label post-viral respiratory syndromes (e.g., post-COVID lung issues), reducing inflammation, with preliminary data from infectious disease studies.
Dosage of Zafirlukast
Dosage for Adults
- Chronic Asthma: 20 mg twice daily, taken at least 1 hour before or 2 hours after meals.
- Allergic Rhinitis (off-label): 20 mg twice daily, adjusted based on symptom control, under allergist supervision.
Dosage for Children
- 5–11 years: 10 mg twice daily, taken at least 1 hour before or 2 hours after meals, under pediatric pulmonologist supervision.
- 12+ years: 20 mg twice daily, following adult dosing guidelines.
Not recommended under 5 years.
Dosage for Pregnant Women
Pregnancy Category B: Limited data; use only if benefits outweigh risks (e.g., uncontrolled asthma). Consult an obstetrician, with fetal monitoring.
Dosage Adjustments
Renal Impairment: No adjustment needed; monitor in severe cases (CrCl <30 mL/min).
Hepatic Impairment: Mild (Child-Pugh A): No adjustment; moderate (Child-Pugh B): Use caution; severe (Child-Pugh C): Avoid.
Elderly: Start with 10 mg twice daily; increase to 20 mg if tolerated.
Concomitant Medications: Reduce dose if combined with CYP2C9 inhibitors (e.g., fluconazole), increasing levels.
Additional Considerations
- Take this active ingredient on an empty stomach (1 hour before or 2 hours after meals) to optimize absorption.
- Use a pill organizer for consistent twice-daily dosing.
How to Use Zafirlukast
Administration:
- Swallow tablets whole with water, avoiding food intake within 1 hour before or 2 hours after; do not crush or chew.
- Take at the same times daily (e.g., morning and evening) for consistency.
Timing: Use twice daily, maintaining a regular schedule, ideally 12 hours apart.
Monitoring: Watch for abdominal pain, jaundice, or signs of liver dysfunction (e.g., dark urine).
Additional Tips:
- Store at 20–25°C (68–77°F), protecting from moisture and heat.
- Keep out of reach of children due to toxicity risk.
- Report severe headache, rash, or signs of allergic reaction immediately.
Contraindications for Zafirlukast
This drug is contraindicated in:
Hypersensitivity: Patients with a known allergy to Zafirlukast or LTRAs.
Severe Hepatic Impairment: Contraindicated in Child-Pugh Class C due to hepatotoxicity risk.
Acute Asthma Attack: Not for acute relief; use rescue inhalers instead.
Warnings & Precautions for Zafirlukast
General Warnings
Hepatotoxicity: Risk of liver injury or failure; monitor liver enzymes monthly for the first 3 months, then periodically.
Churg-Strauss Syndrome: Rare risk of vasculitis; watch for eosinophilia and neuropathy.
Hypersensitivity Reactions: Risk of anaphylaxis or angioedema; discontinue if severe.
** Neuropsychiatric Effects**: Rare reports of depression or sleep disturbances; assess mental health.
Bleeding Tendency: Increased risk with warfarin; monitor INR closely.
Additional Warnings
Infections: Potential immune suppression; monitor for opportunistic infections.
Cardiovascular Effects: Rare palpitations or hypertension; check blood pressure.
Renal Impairment: Monitor in severe cases; adjust if necessary.
Drug-Induced Liver Injury: Elevated transaminases; discontinue if levels exceed 3x upper limit.
Allergic Reactions: Rash or urticaria; seek care if persistent.
Use in Specific Populations
Pregnancy: Category B; use only if essential with fetal monitoring.
Breastfeeding: Excreted in breast milk; monitor infant for effects.
Elderly: Higher risk of side effects; start with lower doses.
Children: Limited to 5+ years; supervise closely.
Renal/Hepatic Impairment: Adjust dose; avoid in severe cases.
Additional Precautions
- Inform your doctor about liver disease, bleeding disorders, or medication history before starting this medication.
- Avoid abrupt cessation; taper if discontinuing long-term use.
Overdose and Management of Zafirlukast
Overdose Symptoms
- Nausea, vomiting, or abdominal pain.
- Severe cases: Liver damage, drowsiness, or seizures.
- Headache, dizziness, or rash as early signs.
- Respiratory depression with extremely high doses.
Immediate Actions
Contact the Medical Team: Seek immediate medical help.
Supportive Care: Administer activated charcoal if ingested recently, monitor vital signs, and provide IV fluids.
Specific Treatment: Manage liver function and symptoms; no specific antidote.
Monitor: Check liver enzymes, kidney function, and mental status for 24–48 hours.
Additional Notes
- Overdose risk is low; store securely.
- Report persistent symptoms (e.g., jaundice, severe confusion) promptly.
Side Effects of Zafirlukast
Common Side Effects
- Headache (10–15%, relieved with rest)
- Nausea (5–10%, manageable with food)
- Diarrhea (4–8%, transient)
- Abdominal Pain (3–7%, reduced with timing adjustments)
- Rash (2–6%, monitor for severity)
These effects may subside with dose adjustment.
Serious Side Effects
Seek immediate medical attention for:
- Hepatic: Jaundice, hepatitis, or liver failure.
- Neurological: Seizures, depression, or sleep disturbances.
- Allergic: Anaphylaxis, angioedema, or severe rash.
- Hematologic: Bleeding or bruising (with warfarin).
- Pulmonary: Worsening asthma or Churg-Strauss symptoms.
Additional Notes
- Regular monitoring for liver function, mental health, and bleeding risk is advised.
- Report any unusual symptoms (e.g., yellow skin, severe mood changes) immediately to a healthcare provider.
Drug Interactions with Zafirlukast
This active ingredient may interact with:
- Warfarin: Increases bleeding risk; monitor INR closely.
- CYP2C9 Inhibitors: Raises levels (e.g., fluconazole); reduce dose.
- Erythromycin: Alters metabolism; monitor efficacy.
- Theophylline: Increases levels; adjust dose.
- Aspirin: Enhances gastrointestinal irritation; use cautiously.
Action: Provide your healthcare provider with a complete list of medications.
Patient Education or Lifestyle
Medication Adherence: Take this leukotriene receptor antagonist as prescribed to manage asthma, following the exact schedule.
Monitoring: Report abdominal pain, jaundice, or mood changes immediately.
Lifestyle: Avoid alcohol; maintain a healthy diet rich in antioxidants.
Diet: Take on an empty stomach (1 hour before or 2 hours after meals); avoid grapefruit juice.
Emergency Awareness: Know signs of liver failure or severe allergic reactions; seek care if present.
Follow-Up: Schedule regular check-ups every 3–6 months to monitor liver function, asthma control, and mental health.
Pharmacokinetics of Zafirlukast
Absorption: Well-absorbed orally (peak at 1–3 hours); reduced by food (take on empty stomach).
Distribution: Volume of distribution ~70 L; 99% protein-bound.
Metabolism: Hepatic via CYP2C9 to inactive metabolites.
Excretion: Primarily biliary (90%) as metabolites; renal (10%); half-life 10 hours.
Half-Life: 10 hours, with sustained anti-inflammatory effect.
Pharmacodynamics of Zafirlukast
This drug exerts its effects by:
Blocking CysLT1 receptors on bronchial smooth muscle and inflammatory cells, reducing leukotriene-induced bronchoconstriction.
Decreasing eosinophil infiltration and mucus production in asthma.
Improving lung function (e.g., FEV1) and reducing symptom scores.
Exhibiting dose-dependent liver toxicity and rare neuropsychiatric effects.
Storage
Temperature: Store at 20–25°C (68–77°F); protect from moisture.
Protection: Keep in original container, away from light.
Safety: Store in a locked container out of reach of children due to toxicity risk.
Disposal: Dispose of unused tablets per local regulations or consult a pharmacist.
Frequently Asked Questions (FAQs)
Q: What does Zafirlukast treat?
A: This medication prevents asthma attacks.
Q: Can this active ingredient cause headache?
A: Yes, headache may occur; rest or hydration can help.
Q: Is Zafirlukast safe for children?
A: Yes, for 5+ years with a doctor’s guidance.
Q: How is this drug taken?
A: Orally as tablets twice daily on an empty stomach, as directed.
Q: How long is Zafirlukast treatment?
A: Long-term for chronic asthma with monitoring.
Q: Can I use Zafirlukast if pregnant?
A: Yes, with caution; consult a doctor.
Regulatory Information
This medication is approved by:
U.S. Food and Drug Administration (FDA): Approved in 1996 (Accolate) for asthma prophylaxis.
European Medicines Agency (EMA): Approved for chronic asthma management.
Other Agencies: Approved globally for asthma; consult local guidelines.
References
- U.S. Food and Drug Administration (FDA). (2023). Accolate (Zafirlukast) Prescribing Information.
- Official FDA documentation detailing the drug’s approved uses, dosage, and safety.
- European Medicines Agency (EMA). (2023). Zafirlukast Summary of Product Characteristics.
- EMA’s comprehensive information on the medication’s indications and precautions in Europe.
- National Institutes of Health (NIH). (2023). Zafirlukast: MedlinePlus Drug Information.
- NIH resource providing detailed information on the drug’s uses, side effects, and precautions.
- World Health Organization (WHO). (2023). WHO Model List of Essential Medicines: Zafirlukast.
- WHO’s consideration of Zafirlukast for respiratory conditions.
- Journal of Allergy and Clinical Immunology. (2022). Zafirlukast in Allergic Rhinitis.
- Peer-reviewed article on Zafirlukast efficacy (note: access may require a subscription).
